Clinical Trials Conference 2017 logo

Assess how to improve your clinical trial performance, from developing novel immunological assays to creating clinical efficacy



As new technologies and personalized vaccines become the norm, the dynamic of clinical trials has to evolve.

This focused clinical development conference will allow you to showcase your services to those who are looking to run new trial models, need support in choosing and gaining approval for different clinical endpoints and want to understand how to get the best out of the information collected.




Clinical Development April 11, Tuesday 11 April 2017

Dr Gregory A. Poland
Clinical Development April 11

Defining vaccine failure and addressing the many factors behind it

  • What do we mean by vaccine failure?
  • What are the factors that have to be in place before we conclude a vaccine “failed"
  • Looking at both immunogenicity and vaccine efficacy
Dr Tyler Martin
Clinical Development April 11

Future of adjuvants – what is needed? Better strategy for a rational design

  • Improving the safety database and performance characteristics of QS-21, one of the leading adjuvant candidates
  • manufacturing sustainable source of synthetic QS-21 for vaccine development and trials
Dr Frank Tomaka
Clinical Development April 11

Encouraging results from clinical studies for a HIV vaccine

  • The need for better animal models to improve HIV vaccine development
  • The effects of changing a single amino acid in the envelope coat protein of naturally occurring HIV strains
  • Overview of clinical trials and vaccine platforms

Networking coffee break

Dr Darin Seehafer
Clinical Development April 11

Collaboration on Government Funded Vaccines Studies

Senior representative, PRA Health Sciences
Dr Robert Janssen
Clinical Development April 11

Gaining regulatory support behind a new and effective Hep B vaccine: Design and results of three Ph III trials

Dr Sally Mossman
Clinical Development April 11

Progress towards a CMV vaccine

  • Human CMV is implicated in a number of diverse diseases
  • Overview of recent vaccine developments and platforms
  • Preclinical progress towards a Pentamer based vaccine

Networking Lunch & Poster Session

Adrian Wildfire
Clinical Development April 11

How can you move your vaccine or biological product from the bench to the market, quickly and safely?

  • Ethics of human challenges models
  • How to proceed best without known correlates of protection?
Professor Stanley Plotkin
Clinical Development April 11

Correlates of protection induced by vaccines with emphasis on enteric vaccines

  • Why are correlates of protection important and how are they determined?
  • Lessons learnt from a collective of vaccine models and studies
  • The need to evaluate the consistency of vaccine production

Networking coffee break

Clinical Development April 11

How do we protect patients from hospital acquired infections?

  • Vaccine development against Clostridium difficile
  • How has the rise an AMR pushed the importance of these infections to immune compromised patients?
Dr Tim Cooke
Clinical Development April 11

A cross-kingdom vaccine against fungal (Candida) & bacterial (Staph aureus) AMR pathogens

  • First efficacy established for an anti-fungal vaccine: Ph IIa results with NDV-3A
  • US Army collaboration using NDV-3A to prevent Staph aureus skin & soft tissue infections
  • NIH clinical study: Hyper-IgE Syndrome patients with recurrent Candida & Staph infections
Dr Veronica Gambillara Fonck
Clinical Development April 11

Bioconjugate Shigella vaccine in clinical development

  • The development plan for a Shigella vaccine demonstrated in PhI and a PhIIB human challenge study
  • A regulatory tool for licensing
Dr Craig Curtis
Clinical Development April 11

Development of Anthrax vaccine candidates

  • Development of single dose nasal spray anthrax vaccine
  • The potential threat to the national health security
  • Combating the health impacts of an anthrax attack

Chair’s closing remarks and close of congress day 2


Networking Drinks & Party

last published: 23/Feb/17 09:39


Clinical Development April 11, Wednesday 12 April 2017


Networking coffee break


Networking Lunch & Poster Session

Dr Alan R. Hinman

The eradication of Polio: Have we succeeded?

-    Measuring and monitoring the success of eradication
-    End game and strategic plan
-    What’s next? Can we eradicate measles?
Professor Robert Daum

A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria

-    Recommendations from the National Vaccine Advisory Committee
-    Use of vaccines to prevent the infections that could or have developed AMR to antibiotics, in adjunction to antibiotic stewardship
-    Examples in Haemophilus influenza, Streptococcus, Staphylococcus aureus

Dr Gregory A. Poland

Panel: How much efficacy is enough? What are the implications of a vaccine no longer being a replacement technology but a companion technology?

-    The concept of partially protected vaccines like malaria, TB, NTDs where the clinical efficacy is no longer 85/90% but closer to 40% 
-    Future of vaccine development 
-    The combining drivers of technology and emerging diseases

More panelists to be announced shortly

Chair’s closing remarks and close of congress

last published: 23/Feb/17 09:39


Sign up for event updates



  • Pharma
  • Biotech
  • National and International Government
  • Academics And Research Institutions ​


  • CEO / CSO / COO
  • CMO / Head of Scientific Affairs
  • Head of Clinical Development
  • Head of Clinical Trial Management / Operations
  • Head of R&D​




  • CROs
  • OEMs / Equipment Manufacturers
  • Platform Technology Providers
  • Big Pharma
  • Biotech